The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen—A single-arm, phase II study of the efficacy of tamoxifen in triple-negative but estrogen receptor beta-positive metastatic breast cancer.
B. E. Kiely
No relevant relationships to disclose
K. Phillips
No relevant relationships to disclose
P. A. Francis
No relevant relationships to disclose
F. M. Boyle
No relevant relationships to disclose
J. F. Forbes
No relevant relationships to disclose
S. B. Fox
No relevant relationships to disclose
L. Murphy
No relevant relationships to disclose
V. Gebski
No relevant relationships to disclose
D. F. Lindsay
No relevant relationships to disclose
R. L. Sutherland
No relevant relationships to disclose
H. Badger
No relevant relationships to disclose